Coronary events are preventable – so don't miss this opportunity: case report

Czech version

Authors: Martin Šatný
Authors‘ workplace: Centrum preventivní kardiologie, III. interní klinika – endokrinologie a metabolismu 1. LF UK a VFN v Praze
Published in: AtheroRev 2025; 10(2): 121-124
Category:

Overview

Although the incidence of acute coronary events has been declining over the past two decades, cardiovascular disease –⁠ predominantly atherosclerotic CVD –⁠ remains the leading cause of morbidity and mortality not only in our country, but also in most developed countries. Currently, as in the treatment of arterial hypertension, rapid escalation of therapy is recommended, in particular the early use of appropriate combination therapy, including modern injectable medications. The presented case study documents current trends in the management of patients at very high cardiovascular risk and emphasizes the importance of lipoprotein(a) testing and early use of PCSK9 inhibitors.

Keywords:

acute coronary syndrome – lipoprotein(a) – cardiovascular risk – PCSK9 inhibitors – atherosclerotic cardiovascular disease

Sources

Cífková R, Bruthans J, Wolhlfahrt P et al. Prevalence hlavních rizikových faktorů kardiovaskulárních onemocnění v české populaci v letech 2015–2018. Studie Czech post-MONICA. Cor et Vasa 2020; 62(1): 6–16. Dostupné z DOI: <http://DX.doi.org/10.33678/cor.2020.010>.

Zdravotnická ročenka 2021. ÚZIS ČR: 2021. Dostupné z WWW: <https://www.uzis.cz/res/f/008435/zdrroccz2021.pdf>.

Národní kardiovaskulární plán 2025. MZ ČR: 2025. Dostupné z WWW: <https://mzd.gov.cz/wp-content/uploads/2025/01/Priloha-3_NKV_plan-souhrnna-analyticka-studie.pdf>.

Roth G, Mensah G, Johnson C et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. J Am Coll Cardiol 2020; 76(25): 2982–3021. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2020.11.010>.

Borén J, Williams KJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol 2016; 27(5): 473–483. Dostupné z DOI: <http://dx.doi.org/10.1097/MOL.0000000000000330>.

Češka R. Číslo LDL žije! AtheroRev 2021; 6(2): 84–89.

Šatný M. Dyslipidemie –⁠ známá neznámá. Vnitr Lek 2023; 69(5): 305–311. Dostupné z DOI: <http://doi.org/10.36290/vnl.2023.060>.

Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111–188. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz455>.

Visseren FL, Mach F, Smulders YM et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42(34): 3227–3337. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehab484>.

Björnson E, Adiels M, Taskinen MR et al. Lipoprotein(a) Is Markedly More Atherogenic Than LDL: An Apolipoprotein B-Based Genetic Analysis. J Am Coll Cardiol 2024; 83(3): 385–395. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2023.10.039>.

[SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration]. SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J 2023 Jul; 44(28): 2544–2556. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehad260>.

Parhofer KG, Aguiar C, Banach M et al. Expert opinion on the integration of combination therapy into the treatment algorithm for the management of dyslipidaemia: the integration of ezetimibe and bempedoic acid may enhance goal attainment. Eur Heart J Cardiovasc Pharmacother 2025 11(4): 367–379. Dostupné z DOI: <http://dx.doi.org/10.1093/ehjcvp/pvaf007>.

Informace dostupné z WWW: www.sukl.cz.

Praluent (alirokumab). Souhrn údajů o přípravku. Dostupné z WWW: <https://www.ema.europa.eu/cs/documents/product-information/praluent-epar-product-information_cs.pdf>.

Repatha (evolocumabum). Souhrn údajů o přípravku. Dostupné z WWW: <https://www.ema.europa.eu/cs/documents/product-information/repatha-epar-product-information_cs.pdf.>

Leqvio (inclisiranum natricum). Souhrn údajů o přípravku. Dostupné z WWW: <https://www.ema.europa.eu/cs/documents/product-information/leqvio-epar-product-information_cs.pdf>.